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ABSTRACT 
Mitochondrial disorders have become the most common cause of inborn errors of metabolism. Impairments in mito- 
chondrial protein synthesis are one of the causes of these diseases, which are clinically and genetically heterogeneous. 
The mitochondrial translation machinery decodes 13 polypeptides essential for the oxidative phosphorylation process. 
Mitochondria protein synthesis depends on the integrity of mitochondrial rRNAs and tRNAs genes, and at least one 
hundred of nuclear encoded products. Diseases caused by mutations in mitochondrial genes as well as in ribosomal 
proteins, translational factors, RNA modifying enzymes, and all other constituents of the translational machinery have 
been described in patients with combine respiratory chain deficiency, and are the object of this review. 
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1. Introduction 
Most of the energy needed by human cells is provided by 
the mitochondrial oxidative phosphorylation (OXPHOS) 
process. OXPHOS couples energy of the electrochemical 
proton gradient generated by the respiratory complexes 
(complex I, III and IV) across the mitochondrial inner 
membrane to produce ATP through ATP synthase (com- 
plex V). Impairments in OXPHOS are generically recog- 
nized as mitochondrial disorders and have become the 
most common cause of inborn errors of metabolism [1,2] 
with a prevalence estimated at 1/5000 birth [3]. Mito- 
chondrial disorders are clinically and genetically hetero- 
geneous. The high incidence and broad heterogeneity 
stems from the dual genetic origin of the respiratory 
complexes. Indeed, respiratory complexes (I, III, IV and 
V) and mitochondrial ribosomes are the best examples of 
cellular components whose assembly depends on two 
genomes; mitochondrial DNA (mtDNA) contributes with 
13 polypeptides in the assembly of respiratory complexes 
whereas 74 proteins constituents of these complexes are 
nuclear encoded. During the evolutionary process mito- 
chondria lost most of mtDNA to the nucleus, however a 
small molecule persist to exit in nearly all eukaryotes. It 
is assumed that changes in the mitochondrial genetic 
code have prevented further loss of mtDNA to the nu- 
cleus. In the mitochondrial translation system AUA 
codes for methionine, UGA codes for tryptophan, AGA  
and AGG are used as stop codons. Mammalian mtDNA 
encoded proteins comprehend: ND1-ND6 subunits of 
complex I, cytochrome b in complex III, COX1, COX2 
and COX3, subunits of complex IV and ATP6 and ATP8 
in complex V. Moreover, mtDNA encodes 12S rRNA, 
16S rRNA and 22 tRNAs [4].  
Therefore, according to their inheritance, mitochon-
drial disorders have been divided in two groups [5]: 1) 
Mutations in the mtDNA. 2) Mutations in the nuclear 
DNA. 
In contrast to nuclear genes, mtDNA molecules are 
present in hundreds or thousands of copies in each cell 
and are maternally inherited. A deleterious mutation in 
mtDNA usually affects some but not all genomes, such 
that cells and tissues will have two populations of 
mtDNA, a situation known as heteroplasmy. If the num- 
ber of mutant mtDNA molecules reaches a certain thre- 
shold, tissue dysfunction and clinical signs will be mani-
fest. This threshold between health and disease will be 
lower in tissues with high energetic demand such as brain, 
muscle and heart [6]. Moreover, mitochondria are not 
equally distributed at cell division and so the propor- tion 
of mutant mtDNA may shift in the daughter cells. 
mtDNA mutations have been described since 1988 
when the first pathogenic mutations were discovered [7]. 
Abnormalities in mtDNA inheritance and maintenance 
are also transmitted as mendelian traits because mtDNA 
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depends on nuclear gene products for its expression and 
stability, and deficiencies in these products lead to de- 
pletion and deletions of mtDNA. These disorders have 
been classified as defects of intergenomic communica- 
tion because mutations of the nuclear DNA disrupt the 
integrity of mtDNA [8]. 
Nevertheless, mitochondrial disorders can arise from 
more than 1200 different nuclear genes mutations that 
directly or indirectly affect OXPHOS [9]. For instance, 
more than three hundred proteins are directly required as 
auxiliary and chaperones that help the assembly of ma- 
ture complexes [10]. Mitochondria are also important for 
the proper exchange of metabolites across the organelle 
membranes, in the biosynthesis of aminoacids, vitamins, 
lipids, prostetic groups (metals, heme, iron-sulfur clus- 
ters), ion homeostasis, and many other intermediates 
which are also required for OXPHOS and cell viability in 
general, deficiencies in any part of this intricate metabo- 
lism may cause disease. 
2. Mitochondrial Gene Expression 
The regulation of mtDNA expression is completely de- 
pendent on nuclear genes but the mechanisms are not 
fully understood [11,12]. Nevertheless, it can be regu- 
lated at different levels: mtDNA copy number; transcript- 
tion initiation; mRNA stability; translation initiation; and 
coordination of respiratory complexes assemblies and 
translation of newly synthesized polypeptides [13]. 
2.1. Mitochondrial Transcription 
Human mtDNA genes are arranged an end to end disp- 
osition with little intergenic regions, their transcription 
occurs in both mtDNA strands generating polycistronic 
RNAs, which are processed into rRNAs, tRNAs and 
mRNAs [4]. Mitochondrial gene expression relies on 
three promoters to generate the respective polycistronic 
RNAs. Mitochondrial RNA polymerase is responsible for 
transcribing the mitochondrially encoded genes, it re- 
quires transcription factors such as TFAM, TFB1M and 
TFB2M [14,15]. TFAM is essential both for transcription 
initiation [15-18] and it is present in mitochondrial nu- 
cleoid controlling mtDNA copy number control [19,20]. 
TFAM packages mtDNA into a compact protein-DNA 
structure termed the nucleoid [20]. Mature mRNAs are 
oligo or polyadenylated at the 3’ end. Terminal 3’ oli- 
goadenylation of mitochondrial mRNAs is essential, be- 
cause processing of several mitochondrial open reading 
frames from the primary polycistronic transcript leaves a 
truncated terminal codon that requires adenylation for 
completion [21]. Polyadenylation is necessary to mRNAs 
stability and to direct them to mitochondrial ribosomes  
for translation [22,23]. In contrast to bacterial mRNAs, 
mitochondrial transcripts lack Shine-Dalgarno sequences. 
2.2. Mitochondrial Translation 
The mitochondrial translation machinery involves mtDNA 
encoded RNAs and a large number of nuclear products 
that can be categorized into proteins necessary for ri-
bosomes assembly; aminoacyl tRNA synthetases; tRNA 
modifying enzymes; initiation factors (IF2-mt and IF- 
3-mt); elongation factors (EFG1, EFG2, EFT, and EFTu); 
termination and release factors, (mtRF1a, mtRF1, 
C12orf65 and ICT1); and ribosomal recycling factors 
(mtRRF1, mtRRF2) [24]. 
Mitochondrial mRNAs translation can be divided into 
four major steps: initiation, elongation, termination and 
ribosome recycling. The initial translation process starts 
at 5’ end with the initiation codon for N-formylmethi- 
onine [25]. Two initiation factors have been identified in 
mammalian mitochondria: IF-2 (IF-2mt) stimulates for-
mylmethionine-tRNA binding to the small ribosomal 
subunit (28S) in the presence of mRNA [26,27], whereas 
IF-3 (IF-3mt) promotes the dissociation of mitochondrial 
55S ribosomes and stimulates initiation complex forma- 
tion [28].  
2.2.1. tRNA Metabolism  
Although mitochondria have a complete set of tRNAs, 
they recognize a broad set of codons [29]. Nevertheless, 
mitochondrial tRNAs need to be processed and edited 
[30] before their recognition by specifics aminoacyl-t- 
RNA synthetases present in the organelle [31]. Aminoa- 
cyl tRNA synthetases catalyze acylation of tRNA with 
their cognates amino acids, but in some cases non-dis- 
criminating attachment can occur [32]. For instance, the 
synthesis of glutaminyl-tRNA involves a non discrimi- 
nating glutamyl tRNA synthetase that charge tRNAGln 
with glutamic acid, generating glutamyl-tRNAGln. The 
transamidation of glutamyl-tRNAGln into glutaminyl-tR- 
NAGln is present in prokaryotes and eukaryotes organ- 
elles [33-37]. Mitochondrial tRNAs are also processed 
and matured by RnaseP and RNaseZ, respectively in- 
volved in the processing of 5’ and 3’ ends [30], as well as 
editing enzymes, such as PUS1, MTO1, TRMU and 
MTFMT. PUS1 is a pseudouridine synthase; pseudouri- 
dylation facilitates base-pairing within the t-RNA secon-
dary structure [38], MTO1 catalyzes the 5-carboxyme- 
thylaminomethylation of the wobble uridine base on 
tRNALys, tRNAGlu, tRNAGln, which improves the fidelity 
in the protein synthesis process [39]. Likewise, TRMU is 
responsible for the 2-thiolation of the wobble U in 
tRNALys, tRNAGlu, tRNAGln [40]. MTFMT is responsible 
for the formylation of methionine-tRNAMet and therefore 
requested for translation initiation [41]. 
2.2.2. Ribosomes Biogenesis 
The processed mRNAs are translated in mitochondrial 
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ribosomes, interacting with the mitochondrial inner me- 
mbrane to ensure the insertion of the newly synthesize 
polypeptides [42]. In yeast several proteins have already 
been shown to facilitate this interaction [24]. Neverthe- 
less, mitochondrial ribosomes have preserved some pro- 
karyotic characteristics such as sensitivity to amynogly-
cosides chloroamphenicol and erythromycin [43]. More- 
over, about half of mitochondrial ribosome proteins have 
bacterial homologues [44]. However, in human, they 
present lower rRNA and higher protein content; because 
of that, even with a 55S sedimentation coefficient they 
are bigger than 70S bacterial ribosomes. The small and 
large subribosomal particles have sedimentation coeffi- 
cients of 28S and 39S, respectively [45]. The small 28S 
subunit is constituted of 12S rRNA and 30 proteins while 
the large 39S subunit constitutes of 16S rRNA and 48 
proteins [46,47]. Not unlike the respiratory complexes, 
assembly of mitochondrial ribosomes depends on the 
coordination of nuclear gene products and mtDNA pro- 
ducts a process that is also assisted by other chaperones 
and regulatory proteins, however little is known about 
them, in yeast the mitochondrial GTPases 1, 2 and 3 
(Mtg1, Mtg2, and Mtg3) assist the assembly of large and 
small subunit [48-51]. Human Mtg1, ObhH1, C7orf30 
are involved in the assembly of the large subunit [51,52], 
whereas Era-like1 and C4orf14 in the assembly of the 
small subunit [53,54]. 
2.2.3. Translational Process 
Mitochondrial translation process also requires specific 
proteins that recognize their respective mRNAs to acti- 
vate translation [55]. In yeast translational activators 
recognize 5’-UTRs of mitochondrial mRNA in a sub- 
strate specific manner, promoting a new level for mito- 
chondrial protein synthesis regulation. Curiously, these 
activators can be part of feedback control loops, allowing 
translation only when the assembly of the respective res- 
piratory complex is being correctly performed [13]. 
The elongation factors: EFTu, EFTs, EFG are nece- 
ssary for the sequential addition of amino acids to the 
growing polypeptide chain. EFTu associate with all am- 
inoacyl-tRNA substrates, discriminating those misch- 
arged [56]. The aminoacyl-tRNA is delivered to the ri- 
bosome “A” site complexed with EFTu and GTP; after 
codon-anticodon interaction and consequent GTP hy- 
drolysis, EFTu-GDP is recycled by EFTs. EFGs cata- 
lyzes the translocation step in which the deacylated 
tRNA in the “P” site is moved to the exit site (“E”) [24]. 
Only two stop codons terminate translation in human 
mitochondria, either UAG and UAA are recognized by 
the release factors RF1a/RF1L, which promote hydroly- 
sis of the ester bond between the tRNA the newly syn- 
thesized polypeptide [24]. Three putative ribosomes re-
cycling factors RRF1, RRF2 and C12orf65 have been 
identified in mitochondria being responsible for the re-
lease of ribosomes from mRNA [57]. 
3. Mitochondrial Protein Synthesis  
Deficiencies 
Mitochondrial protein synthesis deficiencies stems from 
mutations in any part of the mitochondrial translational 
machinery discussed above, including tRNAs, rRNAs 
(mtDNA encoded), as well as from mutations in nuclear 
genes involved in the process.  
3.1. MtDNA Mutations: tRNA and rRNA  
Genes  
Complete loss of any of the mitochondrial rRNAs or 
tRNAs should be lethal. Milder mutations causing de- 
creased stability of tRNAs or rRNAs, should decrease 
mitochondrial translation and cause disease [58].  
Mutations in all mitochondrial tRNAs have been ass- 
ociated with disease, and represent a large proportion of 
mitochondrial disorders. More than 150 mutations in 
tRNA gene have already been described [59,60]. For 
instance, tRNA mutations account for most of mitochon- 
drial encephalomyopathy with lactic acidosis and stroke- 
like episodes (MELAS) and for syndrome myloclonus 
epilepsy with ragged red fibers known as MERRF cases 
[58].  
MELAS is a progressive neurodegenerative disorder 
with typical onset between the ages of 2 and 15, it can 
occur in infancy, or as late as adulthood. Stroke-like epi-
sodes, often accompanied by seizures, are the hallmark 
symptom of MELAS and cause partial paralysis, loss of 
vision, and focal neurological defects. The disease is 
maternally inherited and there are at least 17 different 
mutations that can cause MELAS, by far the most preva- 
lent is the A3243G mutation in the tRNALeu(UUR) gene, 
which is responsible for about 80% of the cases and it is 
also present in patients with progressive external oph- 
talmoplegia (PEO) [58]. The A3243 mutation is located 
within a tridecamer sequence, which binds the transcrip- 
tion terminator factor mTERF. The binding of mTERF at 
this site increases the transcription of 12S and 16S rRNA 
genes [61]. 
Mutations in tRNALEU(UUR) reduce both the aminoacy-
lation of tRNALEU(UUR) as well as affect posttranslational 
modifications in the wobble position of tRNALEU(UUR) 
reducing the transcription levels of mitochondria-enc- 
oded proteins. The reduced aminoacylation affects the 
decoding of UUG and UUA while the wobble defect 
specifically diminishes UUG deconding. Curiously, the 
wobble defect specifically alters the expression of ND6 
mitochondria-encoded protein [62]. 
MERRF syndrome is characterized by progressive 
myoclonus, cerebellar ataxia, and muscle weakness. Al- 
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though a few cases of MERRF are sporadic, most cases 
are maternally inherited due to A8344G missense muta- 
tion in tRNALys, [58]. Absence of ophtalmoplegia, pig- 
mentary retinopathy and heart block and lack of mylo- 
clonus distinguish MELAS from MERRF.  
MELAS, MERRF and other systemic neuromuscular 
syndromes such as Kearns-Sayre, frequently have hear- 
ing loss as one of their clinical signs. Nevertheless, the 
typical mutation found in MELAS cases can lead to 
hearing loss without any other neurological symptom 
present [63]. Curiously, while for most mtDNA muta- 
tions the homoplasmic state would be lethal as discussed 
above, homoplasmy of mutant mtDNA is observed in 
maternally inherited hearing loss. The homoplasmic 
A1555G mutation in the mitochondrial 12S rRNA gene 
has been found to be associated with non-syndromic 
deafness and aminoglycoside-induced deafness [64]. In 
the absence of aminoglycosides, the A1555G mutation 
produces a clinical phenotype that ranges from severe 
congenital deafness through moderate progressive hear- 
ing loss of later onset to completely normal hearing [64]. 
Therefore the nuclear background should be determinant 
in the expression of the different phenotypes; accordingly, 
the activity of mitochondrial RNA polymerase transcrip- 
tion factor TFBM1 has been suggested to alter the pene- 
trance of the deafness phenotype [65].  
3.2. Nuclear Mutations: Proteins Involved in the 
Translation Machinery 
Nuclear gene products account for all proteins involved 
in the translation machinery. However, the number of  
mitochondrial translation impairments that lead to dis- 
ease caused by genetically defined defects of nuclear 
genes is still small (Table 1). 
3.2.1. Ribosome Biogenesis and Proteins 
Altogether the mitochondrial ribosome subunits are co- 
nstituted with 80 proteins [46,47], only 3 have been 
firmly linked to mitochondrial disease, MRPS16, MR- 
PS22 and MRPL3 [60]. 12S rRNA surrounds MRPS16 
protein in the ribosome small subunit. Consequently 
truncated versions of MRPS16 diminish the mitochon- 
drial content of 12S rRNA. Patients with mutated MR- 
PS16 was described with agenesis of corpous callosum , 
dysmorphism and fatal neonatal lactic acidosis with de- 
creased complex I and IV activity in muscle [66]. MR- 
PS22 has no bacterial homolog, but likewise MRPS16 it 
is located in the ribosome small subunit and affects 12S 
rRNA stability. One patient with MRPS22 homozygous 
mutation presented antenatal skin oedema, hypotonia, 
cardiomyopathy and tubulopathy [67]. 
Recently it was shown that patients with mutations in 
the RMND1 gene present impaired mitochondrial trans- 
lation [68-70]. Defective RMND1 lead to lower steady 
state level of ribosome subunits MRPL13, MRPL32, 
MRPS2, as well as lower content of 16S rRNA indicat- 
ing a role for RMND1 in the assembly or maintenance of 
mitochondrial ribosome [68,70]. 
3.2.2. Aminoacyl-tRNA Synthetases 
Aminoacyl tRNA synthetases catalyze acylation of tRNA 
with their cognates amino acids in both cytoplasm and  
 
Table 1. Nuclear genes associated with the mitochondrial translational machinery. 
Biological process Genes involved Genes mutations Clinical Categories 
Ribosome proteins MRPS 1 - 29 MRPL 1 - 48 
MRPL3, 
MRPS16, MRPS22 
Neonatal, Infatile Cardiomyopathy, 
lactic acidosis 
Rib.39S sub. assembly Mtg1, Obh1 C7orf30   
Rib.28S sub. assembly Era-like1 C4orf14   
Ribosomes assembly RMND1 RMND1 Neonatal, encephalopathy,  cardiomyopathy 
tRNA processing and editing RnaseP, RnaseZ,  PUS1, TRMU, MTO1, MTFMT 
PUS1, TRMU, 
MTO1, MTFMT 
Infantile, juvenile, myopathy, lactic 
acidosis 
Translation activators TACO1, LRPPRC, TACO1, LRPPRC Infantile, juvenile, Leigh syndrome. 
Aminoacyl-tRNA synthetases xARSs 
DARS2, RARS2, EARS2, MARS2, 
YARS2, HARS2, AARS2, SARS2, 
FARS2 
Neonatal-juvenile onset,  
Leukoencephalopathy, high lactate, 
MLASA, cardiomyopathy, Perrault 
syndrome 
Initiation factos IF2, IF3   
Elongation Factors EFG1, EFG2, EFT, EFTu EFG1, EFTu, EFT Neonatal, encephalopathy, lactic acidosis, leukoencephalopathy 
Termination Factors MtRF1a, mtRF1, ICT1, C12orf65, C12orf65 Infantile, Leigh syndrome 
Recycling factos RRF1, RRF2, EFG2   
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mitochondria compartments. Mitochondria use 19 dif- 
ferent Aminoacyl t-RNA synthetases, two of them are 
also present in the cytosol (glycyl-tRNA synthetase and 
lysil-tRNA synthetase), and the one missing is the gluta- 
minyl-tRNA synthetase. As explained before, the synthe- 
sis of glutaminyl-tRNA involves a non discriminating 
glutamyl tRNA synthetase that charge tRNAGln with glu- 
tamic acid, generating glutamyl-tRNAGln which is modi- 
fied to glutaminyl-tRNA after a transamidation reaction 
[35]. Patients with deleterious mutation in mitochondrial 
arginyl-tRNA synthetase (RARS2), aspartyl-tRNA syn- 
thetase (DARS2), seryl-tRNA synthetase (SARS2), ty- 
rosyl-tRNA synthetase (YARS2) and histidyl-tRNA sy- 
nthetase (HARS2) have already been described [71-75]. 
Their clinical conditions are very heterogeneous, with 
symptoms ranging from pontocerebellar hypoplasia, 
leukoencephalopathy, hyperuricemia, pulmonary hyper- 
tension, renal failure, alkalosis, ovarian dysgenesis, sen- 
sorineural hearing loss, HUPRA and MLASA syndromes 
[76]. 
3.2.3. Translational Activators 
TACO1 and LRPPRC are the only mitochondrial transl- 
ational activators already described in human. Both are 
COX1 activators and have been identified in human pa- 
tients with Leigh syndrome [77,78]. Considering the 
number of translational activators for mitochondrial en- 
coded polypeptides already described in other organisms 
such as Saccharomyces cerevisiae as well as their im- 
portance in coordinate translation and the modular as- 
sembly of the respiratory complexes (Costanzo and Fox, 
1988; Herrmann et al., 2011) it is expected that our 
knowledge of human translational activators will in- 
crease in the next years with the massive parallel se- 
quencing of patients. 
3.2.4. Translational Factors 
Patients with mutations in the elongation factors EFG1, 
EFTs, EFTu, [79-82] and in the termination factor 
C12orf65 have already been described [57]. Mutations of 
these genes are relatively rare and result in globally de- 
creased mitochondrial translation in cultured skin fibro- 
blasts of patients [59]. Curiously, an EFG1 mutation was 
associated with combined decrease of activity in the res- 
piratory complexes in fibroblasts but not in muscle [83]. 
C12orf65 mutations were detected in patients with en- 
cephalomyopathy and the gene product seem to play a 
role in recycling abortive peptidyl-tRNA species release 
from the ribosome during the elongation phase of trans- 
lation [57].  
3.2.5. tRNA Modifying Enzymes 
Nuclear products that affect mitochondrial tRNAs pro- 
cessing can also cause disease, patients with mutations in 
PUS1, TRMU, MTO1 and MTFMT have been recently 
described [38,41,84-86]. PUS1 mutations were identi- 
fied in patients with mitochondrial myopathy and sidero-  
blastic anemia (MLASA) [84]. TRMU and MTO1 muta- 
tions affect the penetrance of A1555G mutation in the 
mitochondrial 12S rRNA gene [65]. However, mutations 
in these two genes can also cause more severe clinical 
conditions. TRMU patients with fatal infantile liver fai- 
lure [41] and MTO1 patients with cardiomyopathy and 
lactic acidosis have been described recently [85]. Finally 
MTFMT mutations were identified in children with Le- 
igh syndrome and impaired mitochondrial translation 
initiation [86]. 
4. Conclusion and Prospects 
Impairment of mitochondrial protein synthesis diseases is 
an important medical area to be studied. Defects in mi- 
tochondrial translation produce a diverse clinical phenol- 
type, with the most severe presenting in infancy as 
metabolic disorders. In the last years, the proteomic stu- 
dies and high throughput gene sequencing analyses have 
succeeded in identifying new factors involved in mito-
chondrial translation. 
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